During the past decade, Xenoscience, Inc (102) conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Xenoscience, Inc (102)" are "Parkinson Disease" (1 trials) and "Parkinson's Disease (Disorder)" (1 trials). Many other conditions were trialed in "Xenoscience, Inc (102)" in a lesser frequency.

Most popular intervention types in "Xenoscience, Inc (102)" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "IPX203 140 mg" (1 trials), "IPX203 210 mg" (1 trials), "IPX203 280 mg" (1 trials), "IPX203 350 mg" (1 trials) and "IPX203 ER CD-LD" (1 trials). Other intervention names were less common.

The vast majority of trials in "Xenoscience, Inc (102)" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Xenoscience, Inc (102)". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Xenoscience, Inc (102), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Xenoscience, Inc (102), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".